Serial No.: 09/825,615 Filed : April 6, 2001

Page 11

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-22 (canceled)

Claim 23 (new): A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject solely after viral steady state is reached an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's viral load prior to any administration of the antibody to the subject.

Claim 24 (new): A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor, (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, and (c) inhibits binding of HIV-1_{JR-FL} gp120 to the CCR5 receptor, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to any administration of the antibody to the subject.

Claim 25 (new): The method of claim 23 or claim 24, wherein the antibody is a monoclonal antibody.

Claim 26 (new): The method of claim 23 or claim 24, wherein the antibody is selected from the group consisting of PA8 (ATCC

Serial No.: 09/825,615 Filed : April 6, 2001

Page 12

Accession No. HB-12605), PA9 (ATCC Accession No. HB-12606), PA10 (ATCC Accession No. HB-12607), PA11 (ATCC Accession No. HB-12608), PA12 (ATCC Accession No. HB-12609) and PA14 (ATCC Accession No. HB-12610).

Claim 27 (new): The method of claim 23 or claim 24, wherein the antibody is PA14 (ATCC Accession No. HB-12610).

Claim 28 (new): The method of claim 23 or claim 24, wherein after treatment, the subject's HIV-1 viral load is reduced to 33% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

Claim 29 (new): The method of claim 23 or claim 24, wherein after treatment, the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

Claim 30 (new): The method of claim 23 or claim 24, wherein after treatment, the reduction of the subject's HIV-1 viral load is sustained for a period of time.

Claim 31 (new): The method of claim 30, wherein the period of time is at least one day.

Claim 32 (new): The method of claim 30, wherein the period of time is at least three days.

Claim 33 (new): The method of claim 30, wherein the period of time is at least seven days.—-

Claim 34 (new): The method of claim 23 or claim 24, wherein the effective amount of the antibody is between about 1mg and about

Serial No.: 09/825,615 Filed : April 6, 2001

Page 13

50mg per kg body weight of the subject.

Claim 35 (new): The method of claim 34, wherein the effective amount of the antibody is between about 2mg and about 40mg per kg body weight of the subject.

Claim 36 (new): The method of claim 35, wherein the effective amount of the antibody is between about 3mg and about 30mg per kg body weight of the subject.

Claim 37 (new): The method of claim 36, wherein the effective amount of the antibody is between about 4mg and about 20mg per kg body weight of the subject.

Claim 38 (new): The method of claim 37, wherein the effective amount of the antibody is between about 5mg and about 10mg per kg body weight of the subject.

Claim 39 (new): The method of claim 23 or claim 24, wherein the antibody is administered at least once per day.

Claim 40 (new): The method of claim 23 or claim 24, wherein the antibody is administered daily.

Claim 41 (new): The method of claim 23 or claim 24, wherein the antibody is administered every other day.

Claim 42 (new): The method of claim 23 or claim 24, wherein the antibody is administered every 6 to 8 days.—

Claim 43 (new): The method of claim 23 or claim 24, wherein the antibody is administered weekly.

Serial No.: 09/825,615 Filed : April 6, 2001

Page 14

Claim 44 (new): The method of claim 23 or claim 24, wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.

Claim 45 (new): The method of claim 23 or claim 24, wherein the subject is a human being and the antibody is a humanized antibody.